New Kits for July 2026!
Revvity just announced their latest kit launch for July 2026.
We’ve expanded our immunoassay portfolio with 46 new kits covering 35 unique targets across oncology, inflammation, and more—plus two new reagents for GPCR and ADC internalization studies.
The launch includes HTRF, pHSense, and our AlphaLISA SureFire Ultra platform, including AlphaLISA SureFire Biotin-Free and our first-ever AlphaLISA SureFire Ultra Multiplex Biotin-Free formats.
See What’s New Across Our Technologies:
HTRF:
Ideal Applications: Molecular interactions, including protein-protein interactions, kinase activity, receptor-ligand binding, and epigenetic modifications, as well as biomarker and cytokine measurement.
Therapeutic Area | Targets |
Oncology |
|
Inflammation |
|
Ideal Applications: Antibodies and antibody-Drug Conjugates (ADC) internalization monitoring, as well as GPCR and receptor internalization.
Application | Targets |
Antibody & GPCR Internalization |
|
Ideal Applications: Protein phosphorylation, post-translational modifications, and intracellular signaling cascades. Also well-suited for PROTAC and protein degradation studies.
If biotin interference is a concern in your studies, AlphaLISA SureFire Biotin-Free kits and our first-ever AlphaLISA SureFire Ultra Multiplex Biotin-Free formats are available.
Format | Therapeutic Area | Targets |
AlphaLISA SureFire Ultra | Oncology | Inflammation | Virology |
|
AlphaLISA SureFire Biotin-Free | Oncology |
|
Inflammation | Autoimmunity |
| |
Rare Disease |
| |
Cardiovascular |
| |
AlphaLISA SureFire Ultra Multiplex Biotin-Free | Oncology | Autoimmunity |
|
Did you find your target on the list?
Explore the complete July launch here: Revvity's Newest Assay Kits
Reach out to Ashish Chougule (Ashish.Chougule@Revvity.com) for more information.
Images
Additional Info
Media Contact : Ashish Chougule
Related Links : Ashish.Chougule@Revvity.com
